Enlivex Therapeutics Ltd. is a clinical stage that develops innovative immunotherapies based on reprogramming of macrophage. Macrophages are immune cells that can either promote or suppress inflammation and tissue repair, depending on their condition. Enlivex aims to restore the balance between macrophages in diseases where they are not synchronized, such as sepsis, Covid-19 and solid cancer.
The company was founded in 2005 as a spin-off from the Hebrew University of Jerusalem and is headquartered in Nes-Ziona, Israel. It is listed on Nasdaq under the Ticker symbol EnLV and has a market value of approximately $ 92.8 million from May 2023.
Enlivex’s Vision is to establish new equilibrium that solves complex diseases by utilizing the power of macrophages. Its leading product candidate, Allocetra ™, is a cell-based therapy that reprograms macrophages from a pro-inflammatory to an anti-inflammatory condition and thus improves their ability to solve inflammation and promote tissue count.
Allocetra ™ is currently being tested in several clinical studies for various indications, including organ failure associated with sepsis, advanced solid tumors with peritoneal metastases and covid-19. The company has been given parental leave designation from the FDA and the EU for sepsis and peritoneal carcinomatosis, as well as a special life -threatening regulation from the EU that can enable approval after marketing after sepsis.
Basic: 2005
Head office: Nes Zion, Israel
Website: https://www.enlivex.com/
